Oportun Financial Corporation - common stock (OPRT)
5.1700
+0.0800 (1.57%)
NASDAQ · Last Trade: Nov 28th, 6:50 PM EST
One fund just walked away from a rising offshore driller—here’s what long-term investors should make of the move.
Via The Motley Fool · November 27, 2025
A fast-growing niche segment may be the real reason this small-cap consumer products stock is drawing new institutional attention.
Via The Motley Fool · November 27, 2025
One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.
Via The Motley Fool · November 27, 2025
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · March 21, 2025

OPRT stock results show that Oportun Financial beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024

Via Benzinga · May 13, 2024

OPRT stock results show that Oportun Financial beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024

Via Benzinga · April 24, 2024

Via Benzinga · April 23, 2024

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.
Via Benzinga · March 12, 2024

The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500.
Via InvestorPlace · December 2, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1% on Tuesday The Dow traded up 0.21% to 34,166.89 while the NASDAQ rose 1.09% to 13,666.65. The S&P 500 also rose, gaining, 0.41% to 4,383.80.
Via Benzinga · November 7, 2023

Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
Via Benzinga · November 7, 2023




